GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
Greenwich LifeSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$15.21+0.66 (+4.54%)
Close on Oct 19, 2026
- Market cap
- $222.39M
- P/E (TTM)
- –
- Dividend yield
- –
Greenwich LifeSciences, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -3068.2%
Financial strength
- Current ratio
- 1.54
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 154.1%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 71.35
- Dividend yield
- –